AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 86 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2021. The put-call ratio across all filers is 0.11 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $816 | -35.4% | 79,213 | +3.3% | 0.00% | -33.3% |
| Q2 2023 | $1,264 | +210.6% | 76,685 | +72.2% | 0.00% | +200.0% |
| Q1 2023 | $407 | +40.3% | 44,535 | +9.6% | 0.00% | 0.0% |
| Q4 2022 | $290 | -99.8% | 40,631 | +24.3% | 0.00% | – |
| Q3 2022 | $163,000 | +328.9% | 32,689 | +108.4% | 0.00% | – |
| Q2 2022 | $38,000 | -65.5% | 15,689 | -2.8% | 0.00% | – |
| Q1 2022 | $110,000 | -9.8% | 16,136 | +6.6% | 0.00% | – |
| Q4 2021 | $122,000 | -25.6% | 15,136 | -9.7% | 0.00% | – |
| Q3 2021 | $164,000 | +29.1% | 16,757 | -11.2% | 0.00% | – |
| Q2 2021 | $127,000 | -31.7% | 18,877 | -8.3% | 0.00% | -100.0% |
| Q1 2021 | $186,000 | +100.0% | 20,577 | +47.7% | 0.00% | – |
| Q4 2020 | $93,000 | +25.7% | 13,927 | -5.8% | 0.00% | – |
| Q3 2020 | $74,000 | -35.7% | 14,777 | +3.8% | 0.00% | – |
| Q2 2020 | $115,000 | – | 14,242 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
| COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
| GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
| Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
| Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
| Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
| Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
| Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
| RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
| FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |